Genenta Science S.p.A. reports developments spanning its biotechnology heritage and its strategic shift toward an industrial consolidation model in Italian national-security-regulated sectors. News items cover the company’s Nasdaq-traded ADSs, capital structure, operating and financial results, and governance actions tied to the expanded corporate purpose approved under Italy’s Golden Power framework.
Company updates also include the Temferon hematopoietic stem-cell gene therapy platform for solid tumors, clinical findings in glioblastoma multiforme, and efforts to evaluate collaboration opportunities for the biotechnology platform. Recent corporate news has also addressed defense, aerospace, cybersecurity, biotechnology, and biosecurity themes as Genenta evaluates and pursues industrial integrations.
Genenta Science (GNTA) announced it will do business as Saentra Forge, adopting a new identity for its industrial consolidation strategy. Its American Depositary Shares (ADSs) are expected to begin trading on the Nasdaq Capital Market as SAEN at the opening of trading on November 4, 2026.
The identity reflects the transformation announced in January 2026, focused on acquiring majority or full ownership of companies in security-regulated sectors, including aerospace, defense, biotechnology and biosecurity. The legal name remains Genenta Science. A new logo, visual identity and website will roll out across communications and digital channels from November 4.
Genenta Science (Nasdaq: GNTA) received a Nasdaq notification on October 16, 2026, that it failed the minimum bid price requirement. Its American Depositary Shares (ADSs) closed below $1.00 for 30 consecutive business days, from September 3 through October 15, 2026.
The notice does not cause immediate delisting. Genenta has until April 14, 2027 to regain compliance, requiring a closing bid of at least $1.00 per ADS for at least 10 consecutive business days, unless Nasdaq extends that period. An additional 180-calendar-day compliance period is conditional on eligibility requirements. Shareholders have already approved a 1-for-10 to 1-for-20 reverse split, which the board may implement if appropriate. Genenta plans to monitor its ADS price and evaluate compliance options.
Genenta Science (GNTA), which is evolving into Saentra Forge, reported that portfolio company Sòphia High Tech supplied the Spring Assembly hardware used in the second/third-stage separation system of the VEGA-C VV30 launch on September 15, 2026.
The European launcher, built and operated by Avio, carried the Copernicus Sentinel-3C and FLEX Earth observation satellites into Sun-synchronous orbit from Europe’s Spaceport in Kourou. Sòphia HT has been in serial production of the Spring Assembly for VEGA-C since 2018. Installed between the Zefiro 40 second stage and Zefiro 9 third stage, the assemblies store and release elastic energy in a controlled way to initiate clean stage separation under defined kinematic conditions, limiting rotation, interference and abnormal loads.
The component’s performance depends on tight control of geometry, materials and process, and Sòphia HT’s work is highlighted as an example of precision engineering supporting European space missions.
Genenta (Nasdaq: GNTA)-backed Sòphia High Tech, an Italian aerospace and defense manufacturer, announced ROMAN, a robotic arm for remote inspection and maintenance inside the RFX-mod2 nuclear fusion research machine, where plasma can reach about 20 million °C.
Developed with the University of Naples Federico II’s Department of Industrial Engineering and Herobots, ROMAN can visually inspect, clean, and remove or reinstall individual graphite tiles on the machine’s inner wall. According to Sòphia HT, the project extends its precision-engineering capabilities from rockets, satellites, and defense into nuclear technology, adding a reference in a mission-critical, highly regulated market and aligning with Genenta’s strategy to build a cross-sector industrial platform, which may be renamed Saentra Forge subject to shareholder approval.
Genenta (Nasdaq: GNTA), which is evolving into Saentra Forge subject to shareholder approval, reported that Genenta‑backed Sòphia High Tech approved unaudited FY2025 results. Sales rose 29.3% to €7.17 million and total value of production increased 34.7% to €8.47 million.
EBITDA grew 68.1% to €1.61 million, lifting the EBITDA margin by about 380 bps to 19.0%, while operating profit advanced 80.8% to €1.21 million. Sòphia HT appointed a new Board combining founder leadership with Genenta representatives. According to Genenta, it owns about 19% of Sòphia HT, has contractual rights to increase to 51% but does not currently consolidate Sòphia HT’s results; the Italian‑GAAP, non‑GAAP figures may change and should not be considered U.S. GAAP or IFRS data.
Genenta (Nasdaq: GNTA) signed definitive agreements to invest a total of €6.0 million in Sòphia High Tech in two tranches to acquire a 19.9% stake after tranche one and a 51% majority stake after tranche two.
Sòphia HT reported 2024 revenues of ~€6.29 million and EBITDA of ~€0.96 million, expects ~€8 million sales for 2025, and projects roughly doubling 2024 revenue and growing headcount from 44 to ~70 by 2027. Proceeds will fund capacity scale‑up, insourcing, automation, and commercial expansion.
Genenta (Nasdaq: GNTA), evolving into Saentra Forge, signed a binding offer to fund Italian aerospace manufacturer Sòphia High Tech via two reserved capital increases for a potential controlling stake upon performance milestones. Genenta expects to fund EUR 6.0 million in two tranches to scale production, technology, and commercial reach; the deal is subject to due diligence, approvals, and definitive documentation.
Sòphia HT is profitable, forecasts EBITDA growth for 2026–2027, employs 40+ engineers and has completed over 530 projects serving ESA, AVIO, Leonardo, MBDA and others.
Genenta (Nasdaq: GNTA) announced on March 24, 2026 that it is evolving into Saentra Forge, an industrial consolidator targeting biotech, defense, aerospace and national-security technologies. The company said it is working with DC Advisory to explore collaboration opportunities for its original biotechnology platform, but has no active discussions regarding Temferon to date.
Management emphasized continued pursuit of partners given prior preliminary clinical data, founder-scientists' ongoing shareholdings, and a strategic shift toward selective acquisitions and industrial aggregation.
Genenta (Nasdaq: GNTA), evolving to Saentra Forge (Nasdaq: SAEN), announced on March 13, 2026 that CEO Pierluigi Paracchi was appointed by the Italian government to the Board of Guarantors of the Italian Academy at Columbia University.
The appointment, conferred by Deputy Prime Minister Antonio Tajani and transmitted by Ambassador Marco Peronaci, places the CEO on a 12‑member board that supports the Academy’s research and cultural exchange activities.
Genenta Science (Nasdaq: GNTA), transforming into Saentra Forge (Nasdaq: SAEN), announced appointment of Paolo Salvato to the Board of ATC, marking its first entry into defense manufacturing, and confirmed ongoing evaluation of majority-control acquisitions in regulated national-security sectors. Nature Medicine accepted a manuscript reporting key clinical findings from the company’s Glioblastoma multiforme trial, with publication expected in the coming weeks.
Management said it is prioritizing profitable, majority-controlled industrial scale-ups and evaluating biotech partnerships to reduce capital needs for registrational studies, while retaining flexibility to access U.S. public markets subject to market and regulatory conditions.